ERBB2 and breast carcinoma: HER2 played a major role in the proliferation of breast cancer cells and was affected by betulinic acid treatment, resulting in decreased expression of HER2 and p-HER2, as well as downstream kinases such as mitogen-activated protein kinase (MAPK), p-MAPK, Akt, and p-Akt.